AIGHキャピタルが バイオ医薬品会社であるTarsus Pharmaceuticalsの株式を10%近く増えた AIGH Capital boosted its stake in Tarsus Pharmaceuticals, a biopharmaceutical firm, by nearly 10%.

AIGHキャピタルマネジメントはタルサス製薬への投資を9.9%増やし,現在224,713株を所有し,同社の10番目に大きな保有株となりました. AIGH Capital Management LLC increased its investment in Tarsus Pharmaceuticals by 9.9%, now owning 224,713 shares, making it the firm's 10th largest holding. 眼科を専門とする生物製薬会社であるTarsus Pharmaceuticalsは,白炎と梅ボミア腺疾患の治療にXDEMVYという主要候補製品を持っています. Tarsus Pharmaceuticals, a biopharmaceutical company focusing on eye care, has a lead product candidate, XDEMVY, for treating blepharitis and meibomian gland disease. 株価は"買取"の評価と平均目標価格63.67ドルです. The stock has a consensus "Buy" rating and an average target price of $63.67. 機関投資家はタルサス製薬の株式の90.01%を保有しており,最近はAIGHとPrudential Financial Inc.から買収した. Institutional investors hold 90.01% of Tarsus Pharmaceuticals' stock, with recent buys from AIGH and Prudential Financial Inc.